Tissue expression microarrays, employed to determine the players and mechanisms leading to prostate cancer development, have consistently shown that myosin VI, a unique actin-based motor, is upregulated in medium-grade human prostate cancers. Thus, to understand the role of myosin VI in prostate cancer development, we have characterized its intracellular localization and function in the prostate cancer cell line LNCaP. Using light and electron microscopy, we identified myosin VI on Rab5-positive early endosomes, as well as on recycling endosomes and the trans-Golgi network. Intracellular targeting seems to involve two myosin VI-interacting proteins, GIPC and LMTK2, both of which can be coimmunoprecipitated with myosin VI from LNCaP cells. The absence of Disabled-2 (Dab2), a tumour suppressor and myosin VI-binding partner, inhibits recruitment of myosin VI to endocytic structures at the plasma membrane in LNCaP cells, but interestingly has no effect on endocytosis. Small interfering RNA-mediated downregulation of myosin VI expression results in a significant reduction in prostate-specific antigen (PSA) and vascular endothelial growth factor (VEGF) secretion in LNCaP cells. Our results suggest that in prostate cancer cells, myosin VI regulates protein secretion, but the overexpression of myosin VI has no major impact on clathrinmediated endocytosis.
Introduction
Although prostate cancer is the most frequent malignancy detected in men in Western countries, there is a general lack of information regarding the molecular mechanisms involved in the progression of this cancer. To identify the cellular processes and proteins that are involved in the development of prostate cancers, tissue expression microarrays have been used to monitor the changes in gene expression during malignant transformation. Microarray data from 174 human epithelial tumours highlighted myosin VI as one of the genes most frequently overexpressed in prostate and breast cancer tissues (Su et al., 2001 ). Furthermore, the highest level of myosin VI expression was detected in medium-grade androgen-dependent prostate cancers, whereas androgen-independent more advanced and aggressive cancers show less dramatic overexpression (Dunn et al., 2006) . Although these initial observations are intriguing, very little is known about the roles that myosin VI has in human cancers.
In the myosin superfamily, myosin VI has unique cellular properties and functions, because it moves towards the minus end of actin filaments in the opposite direction to all other myosins (Wells et al., 1999) . Myosin VI contains a N-terminal motor domain that binds actin and ATP, a short neck region with bound calmodulin and a C-terminal tail, the cargo-binding domain (Hasson and Mooseker, 1994) . The tail region is alternatively spliced, containing either a large or a small insert, generating at least four different myosin VI splice isoforms with different tissue-specific expression patterns and possible functions (Kellerman and Miller, 1992; Buss et al., 2001) . Myosin VI is ubiquitously expressed in multicellular organisms. In mammalian cells, myosin VI is recruited to membrane ruffles, to cellcell contact sites, into the perinuclear region at/around the Golgi complex and onto clathrin-coated and uncoated endocytic structures (Buss et al., 1998; Buss et al., 2001; Aschenbrenner et al., 2003; Maddugoda et al., 2007) . Functional studies have shown a role for myosin VI in the secretory pathway for the delivery of cargo to the plasma membrane (Warner et al., 2003; Au et al., 2007) , in clathrin-mediated endocytosis (Buss et al., 2001) and in the transport of endocytosed cargo to the recycling compartment . Loss of myosin VI reduces the motility of ovarian and prostate cancer cells (Yoshida et al., 2004; Dunn et al., 2006) , and in Drosophila melanogaster ovaries, it inhibits bordercell migration (Geisbrecht and Montell, 2002) . These diverse roles of myosin VI are mediated by interactions with different binding partners; for example, recruitment of myosin VI to the Golgi complex is mediated by binding to optineurin (Sahlender et al., 2005) , whereas targeting of myosin VI to clathrin-coated structures (CCSs) at the plasma membrane requires binding to Disabled-2 (Dab2) (Morris et al., 2002) . Dab2 is a tumour suppressor gene that is dramatically downregulated in breast, prostate and ovarian cancers, and in a number of cancer cell lines (Schwahn and Medina, 1998; Tseng et al., 1998; Fazili et al., 1999) . On early endosomes and in the recycling pathway, myosin VI interacts with the glucose transporter-binding protein GLUT1CBP (GIPC) (Bunn et al., 1999) and the Ser/Thr transmembrane protein kinase LMTK2 . A genome-wide association study recently identified LMTK2 as one of the three novel common alleles associated with prostate cancer (Eeles et al., 2008) .
As myosin VI is a multifunctional motor protein involved in different cellular pathways, it may promote prostate carcinogenesis by a number of distinct mechanisms/pathways. In prostate cancer LNCaP cells, we observed that myosin VI is present on early endosomes, on recycling endosomes and to a lesser extent on the trans-Golgi network. Myosin VI was not associated with CCSs at the plasma membrane despite the expression of the large insert myosin VI isoform that normally targets this location. GIPC and LMTK2 co-immunoprecipitate with myosin VI from LNCaP cells and reflect myosin VI's cellular localization in the early endosomes and the perinuclear recycling compartment. When myosin VI expression was knocked down, secretion of prostatespecific antigen (PSA), a serine protease of the kallikrein family (Balk et al., 2003) , and the vascular endothelial growth factor (VEGF), a growth factor important for tumour angiogenesis (Ellis and Hicklin, 2008) , were significantly reduced. Thus, myosin VI overexpression may enhance prostate tumour growth and metastasis by increasing the secretion of growth factors and potential extracellular matrix proteases.
Results

Myosin VI isoforms expressed in LNCaP cells
In mammalian cells, splice variants of myosin VI are expressed that contain either no insert (NI), a small insert (9aa), a large insert (LI, 22 or 32aa) or both large and small inserts in the C-terminal tail domain (Kellerman and Miller, 1992; Buss et al., 2001) . The large insert encoded by three different exons of roughly equal size (a, b and c) can be rearranged to form different versions (Dance et al., 2004 ) (see Figure 1A ). Myosin VI isoforms are expressed in a tissue-specific manner; the large insert isoform (abc or bc) is predominantly expressed in polarized epithelial cells, specifically targeting CCSs at the plasma membrane, whereas the NI isoform is mostly present in uncoated endocytic structures and in the perinuclear region at/around the Golgi complex (Buss et al., 2001) . Using reverse transcription PCR, we observed that LNCaP cells express the myosin VI NI isoform and three splice variants of the LI, the long abc, the bc and the ab, whereas the non-malignant prostate cell line PNT1A and HeLa cells express only the myosin VI NI isoform ( Figure 1B ). As the myosin VI LI-abc and bc isoforms target CCSs at the plasma membrane, we expressed green fluorescent protein (GFP)-myosin VI tail constructs of all three LNCaP LI isoforms (abc, bc and ab) in HeLa cells ( Figure 1C ). Whereas the myosin VI tail LI-abc or bc isoforms colocalize with AP2 on CCSs at the plasma membrane as expected, ( Figure 1C , a-c and d-f), the ab isoform is concentrated in the perinuclear region and not at the plasma membrane ( Figure 1C , g-i). As this short version of the LI, missing exon c, is no longer able to target myosin VI to endocytic structures, exon c must have a role in targeting/recruiting myosin VI to CCSs at the plasma membrane.
The subcellular localization of myosin VI in LNCaP cells
In LNCaP cells, overexpression of endogenous myosin VI causes it to accumulate in the cytosol, and as it is not bound to cargo or target membranes, it could be removed by pre-permeabilizing the cells with saponin before fixation (Morriswood et al., 2007) . Under these conditions, myosin VI was observed in a vesicular staining pattern throughout the cell, with high concentrations in cell extensions and in the perinuclear area (Figure 2 ). To characterize the intracellular distribution of myosin VI, we performed double labelling experiments using antibodies to marker proteins for the different subcellular compartments. Although LNCaP cells express myosin VI isoforms containing the LI-abc and bc inserts, no endogenous myosin VI was detected in AP2-positive CCSs at the plasma membrane (Figure 2 , a-c) because of the lack of Dab2 (see Figure 4) . The myosin VI in cell extensions in the cell periphery colocalizes with Rab5 ( Figure 2 d-f ) and the transferrin receptor (TfR) (Figure 2 g-l) , indicating that in LNCaP cells, myosin VI is recruited to early endosomes and is also concentrated in the perinuclear region, where it colocalizes with TGN46, a marker of the trans-Golgi network (Figure 2 m-o), and with TfR, which is present in the endocytic recycling compartment (Figure 2 j-l) . A similar juxtanuclear concentration of myosin VI was recently observed in surgical prostate cancer tissues (Wei et al., 2008) . In the non-malignant prostate cell line, PNT1A, myosin VI colocalizes with TfR and Rab5-positive early endocytic compartment in the cell periphery; however, less myosin VI is present in the perinuclear region at/around the Golgi complex. PTN1A cells do not express the myosin VI LI isoform and, therefore, although Dab2 is present, very little colocalization with AP2 in CCSs at the plasma membrane was detected (Supplementary Figure 1) .
The precise localization of myosin VI in the perinuclear region was investigated at the ultrastructural level. Cryosections of LNCaP cells double labelled with antibodies to myosin VI and TfR or TGN46 show that myosin VI is associated with vesicular and tubular membranes at the Golgi complex, showing partial colocalization with TGN46 ( Figure 3A a) and TfR ( Figure 3A b) . A morphometric analysis was performed to quantify the colocalization of myosin VI with TfR or with TGN46 and determine whether myosin VI is recruited to the perinuclear endocytic recycling com- The tail domain contains two splice insertions: a large insert with a maximum of three exons (a, b and c) and a small insert with a single exon. (B) Myosin VI isoforms expressed in LNCaP, PNT1A or HeLa cells were identified by reverse transcription PCR using primers flanking the large insert and run on a 1.5% agarose gel. Whereas HeLa cells and PNT1A cells express only the no insert (NI) isoform of myosin VI, LNCaP cells express four different isoforms of myosin VI, the NI form and three splice variants of the large insert (LI) abc, ab and bc. (C) The LI-ab splice variant does not target clathrin-coated structures (CCSs) at the plasma membrane. To analyse the targeting of the three splice variants of the large insert to CCSs, the green fluorescent protein (GFP)-tagged myosin VI tails containing either the LI-abc (a), the LI-bc (d) or the LI-ab (g) were expressed in HeLa cells and processed for immunofluorescence microscopy using anti-GFP and anti-AP2 antibodies. As shown in the merged images, the tail LI-abc (a-c) and LI-bc (d-f) isoforms are recruited to CCSs at the plasma membrane, whereas the tail LI-ab (g-i) isoform is present on perinuclear vesicles and shows very little colocalization with AP2 in CCS. partment (TfR) or to the trans-Golgi network (TGN46). In each double labelling experiment, 100 myosin VIassociated gold particles present on a vesicle or tubule were analysed for colocalization with TfR or TGN46 on the same membrane structure. The same length of membrane of about 45 mm was scored in each experiment. Figure 3B shows that 68 out of 100 myosin VI molecules are on a compartment that also contains TfR, whereas only 38 molecules out of 100 myosin VI molecules share a membrane with TGN46, indicating that most of the myosin VI in the perinuclear region is present in the TfR-positive endocytic recycling compartment and less is associated with the trans-Golgi network. The relative amounts of myosin VI associated with either the recycling endosome or the trans-Golgi network compartment were quantified on pictures of the Golgi area at 64 Â K magnification. In both experiments, 100 myosin molecules were assessed for colocalization with either TGN46 or TfR on the same length of membrane (about 45 mm each). To measure the length of the membrane, the number of intersections with the Photoshop 1 cm grid lines were counted (Rabouille et al., 1995) . Whereas 68 out of 100 myosin VI molecules can be found on a membrane compartment also containing the TfR, only 38 out of 100 myosin VI molecules share a membrane with TGN46.
Binding partners of myosin VI in LNCaP cells
As a number of binding partners have been described previously that link myosin VI to specific functions in the endocytic and secretory pathways (Buss and Kendrick-Jones, 2008) , we compared their expression levels in PNT1A and LNCaP cells by western blotting ( Figure 4A ). Myosin VI is highly expressed in LNCaP cells, whereas most binding partners show very little change in expression between normal and malignant prostate cells; however, Dab2 expression is completely absent in LNCaP cells. Dab2 is a tumour suppressor gene that is dramatically downregulated in breast, prostate and ovarian cancers (Schwahn and Medina, 1998; Fazili et al., 1999; Tseng et al., 1998) .
The absence of Dab2 in LNCaP cells may explain why myosin VI is missing from CCSs at the plasma membrane, although the myosin VI LI-abc and bc isoforms are expressed (Morris et al., 2002; Spudich et al., 2007) . To test this suggestion, we re-expressed Dab2 in LNCaP cells and monitored the changes in myosin VI localization ( Figure 4C ). In untransfected cells, myosin VI shows very little overlap with clathrin ( Figure 4C , a-c), whereas in cells expressing Dab2, endogenous myosin VI is now present in CCSs at the plasma membrane ( Figure 4C, d-f ). The expressed Dab2 binds to endogenous myosin VI in LNCaP cells, and both proteins can be co-immunoprecipitated ( Figure 4D ). Thus, in LNCaP cells, absence of Dab2 blocks myosin VI association with endocytic structures at the plasma membrane and allows this myosin VI pool to be available to function in other subcellular compartments.
Of all the binding partners expressed in LNCaP cells, only GIPC and LMTK2 bind to and co-immunoprecipitate with myosin VI ( Figure 4B ). This suggests that in LNCaP cells, GIPC is involved in recruiting myosin VI to the peripheral Rab5-positive early endosomes and LMTK2 may link myosin VI to the perinuclear recycling compartment (see Figures 2 and 3) . Although myosin VI is also present at the trans-Golgi network in LNCaP cells ( Figure 3 ) and we previously showed that optineurin links myosin VI to the Golgi complex, optineurin does not co-immunoprecipitate with myosin VI from LNCaP cells (data not shown).
Clathrin-mediated endocytosis is not compromised in LNCaP cells
In LNCaP cells, as Dab2 is absent, the myosin VI LIabc and LI-bc isoforms are not targeted to CCSs at the plasma membrane. To determine whether this causes defects in cellular uptake of cell-surface receptors, we analysed TfR and epidermal growth factor receptor (EGFR) trafficking in LNCaP cells. First, we assessed clathrin-dependent and ligand-induced EGFR uptake and sorting from endosomes to lysosomes by measuring EGFR endocytosis and EGFR degradation. No dramatic difference in the rate of EGFR uptake was observed in LNCaP compared with myosin VI KD LNCaP cells (Figure 5a ). Furthermore, LNCaP cells showed no delay in EGFR degradation by western blotting compared with HeLa cells, indicating that endocytosis and sorting of EGFR from endosomes to late endosomes/lysosomes is intact (Figure 5b ). We next analysed the uptake and recycling of the TfR. Measuring continuous endocytosis of Tf-Alexa-647 by fluorescence-activated cell sorting (FACS) analysis, we observed a very similar rate of Tf-Alexa-647 uptake in LNCaP cells compared with myosin VI KD LNCaP cells, suggesting that overexpression of myosin VI does not lead to a defect in clathrin-mediated endocytosis (Figure 5c ). To assess the endocytic recycling pathway, the cells were allowed to internalize Tf-Alexa-647 for 30 min at 37 1C, before a chase with unlabelled Tf for varying time points. The amount of Tf-Alexa-647 remaining in the cell was quantified by FACS analysis. Figure 5d indicates that the rate of Tf recycling is very similar in LNCaP and myosin VI KD LNCaP cells, and there is no significant increase or delay in Tf recycling in LNCaP cells. Interestingly, in the electron microscopy, the internalized TfR is localized in vesicular/tubular structures in the perinuclear region close to the Golgi stack ( Figure 5e ). Thus, the absence of Dab2 and myosin VI from CCS at the plasma membrane has no apparent effect on the rate of TfR uptake in LNCaP cells.
We also investigated whether myosin VI is involved in androgen receptor translocation into the nucleus, as myosin VI is specifically overexpressed in androgen-dependent prostate cancer (Dunn et al., 2006) . However, no defects in androgen receptor recruitment into the nucleus were observed in myosin VI KD cells or in cells expressing the dominant-negative myosin VI tail domain (Supplementary Figure 2) .
Myosin VI has a role in PSA and VEGF secretion in LNCaP cells In cells derived from the myosin VI knockout mouse (Snell's waltzer), small interfering RNA (siRNA) knockdown cells or cells overexpressing dominant-negative myosin VI tail mutants, we showed that myosin VI is required for the steady-state organization of the Golgi complex, for post-Golgi membrane traffic and for sorting of newly synthesized transmembrane proteins through the recycling endosome to the basolateral domain in polarized epithelial cells (Warner et al., 2003; Chibalina et al., 2007; Au et al., 2007) . As in LNCaP cells myosin VI is present on tubular/vesicular structures that appear to be part of the trans-Golgi network or the perinuclear recycling endosome, we tested whether myosin VI functions in the secretion of PSA, a serine protease and a member of the kallikrein protein family that is secreted by normal and malignant prostatic epithelial cells and is widely used as a serum prostate cancer biomarker (Balk et al., 2003) . In LNCaP cells, PSA is present in tubular/vesiclular structures in the perinuclear region (Figure 6Aa) , where it colocalizes with TfR ( Figure 6Ab ) and myosin VI (Figure 6Ac ). The localization of myosin VI and PSA in TfR-positive recycling endosomes (Figures 3 and 6) suggests that myosin VI may regulate the delivery of PSA to the plasma membrane, possibly at the level of the recycling endosome. To test this hypothesis, we measured PSA secretion in LNCaP cells transfected with myosin VI siRNA to knockdown myosin VI expression. We achieved a dramatic reduction in myosin VI expression in LNCaP cells and observed a 40% reduction in PSA secretion. Similar results were obtained by overexpressing the different dominant-negative myosin VI tail isoforms in LNCaP cells, in which there was also a 30-40% reduction in PSA secretion ( Figure 6D ). These results indicate that all four myosin VI isoforms may have a role in protein secretion in LNCaP cells.
Finally, we determined whether loss of myosin VI only affects PSA secretion or whether it also affects secretion of the VEGF, which is an important factor released by many tumours that stimulates vascularization and tumour angiogenesis (Ellis and Hicklin, 2008) . Loss of functional myosin VI leads to a reduction in VEGF secretion ranging from 20% in siRNA KD cells to a maximal 40% in LNCaP cells overexpressing the dominant-negative myosin VI tails (Figures 7a and b) . In summary, our results indicate that the overexpressed myosin VI in LNCaP cells enhances exocytosis of PSA and VEGF. We next analysed whether any factors secreted into conditioned medium by LNCaP cells, compared with that released by LNCaP myosin VI KD cells, change the viability of prostate cells (Supplementary Figure 3A) . We observed no significant change in the viability of the prostate cell line PNT1A when grown in conditioned medium harvested from LNCaP myosin VI KD cells compared with those grown in medium from LNCaP cells (Supplementary Figure 3A) . Therefore, the total amount of proteins that is secreted into protein-free conditioned cell culture medium, is not affected by the expression levels of myosin VI in mock-transfected or myosin VI KD LNCaP cells (Supplementary Figure 3B) , clearly indicating that myosin VI selectively enhances exocytosis of only a limited number of secreted factors.
Discussion
In LNCaP cells, in which myosin VI is dramatically overexpressed, we observed that it is involved in To reduce expression of myosin VI in LNCaP cells, the cells were transfected twice with small interfering RNA (siRNA) targeting myosin VI or with non-specific control siRNA (mock). At 2 days after the second transfection, myosin VI depletion was assessed by immunoblotting with antibodies to myosin VI and to calregulin as a loading control. (C) The medium of mock-transfected and myosin VI siRNA knockdown cells was collected and the amount of secreted PSA was measured using a commercially available ELISA (enzyme-linked immunosorbent assay) kit. (D) To assess the role of different myosin VI isoforms for PSA secretion, LNCaP cells were transfected with control pEGFP vector or with the different dominant-negative tail isoforms of myosin VI: GFP-tail NI, GFP-tail LI-abc, GFP-tail LI-ab or GFP-tail LI-bc. Transfected cells expressing GFP-tagged tails were isolated by fluorescence-activated cell sorting and grown for 48 h before the PSA concentration in the medium was determined by ELISA. GFP, green fluorescent protein; LI, large insert; NI, no insert.
secretion of the prostate-specific marker, PSA, and the endothelial growth factor, VEGF. Downregulation of myosin VI expression in LNCaP cells by siRNAmediated knockdown, reduces secretion of PSA and VEGF by about 40%, indicating that myosin VI overexpression in prostate, and also probably in other human cancer tissues (Yoshida et al., 2004; Dunn et al., 2006) , may be linked to elevated protein secretion. These cancer tissues are derived from epithelial cells, which are specialized secretory cells that line ducts and cavities in tissues. At present, it is unclear why myosin VI is specifically overexpressed in these secretory adenocarcinomas and how exactly upregulation of secretion generates a malignant tissue.
Prostate-specific antigen is the most widely used biomarker for prostate cancer detection, and there is now increasing evidence that it has a pathophysiological role in prostate cancer biogenesis (Whitbread et al., 2006) . It has been shown that secreted PSA can increase cellular migration in two ways by either promoting epithelial-mesenchymal cell transition (Veveris-Lowe et al., 2005; Lawrence et al., 2007) or by cleaving extracellular matrix proteins (Borgono and Diamandis, 2004; Clements et al., 2004) , which could propagate the invasiveness of prostate carcinoma cells. It is, therefore, conceivable that the upregulation of PSA secretion, caused by the overexpression of myosin VI, may support prostate cancer growth. Similarly, VEGF is a key angiogenic factor that has several roles in the complex process of blood vessel formation required for tumour growth (Hicklin and Ellis, 2005) . VEGF mediates numerous changes within the tumour including the recruitment and cell proliferation of endothelial precursor cells by binding to its own cognate tyrosine kinase receptor on the surface of endothelial cells (Ellis and Hicklin, 2008) . Therefore, an increase in VEGF secretion in cells overexpressing myosin VI could be a significant factor promoting tumour growth.
Although myosin VI could be involved in endocytosis, exocytosis and/or cell migration in LNCaP cells, we clearly show that myosin VI has an important function in protein secretion. In NRK cells, we observed that myosin VI's role in secretion was mediated by interaction with optineurin, which links it to the Golgi complex (Sahlender et al., 2005) . In LNCaP cells, however, very little optineurin binds to and can be co-immunoprecipitated with myosin VI, and in these cells, far less myosin VI is associated with the trans-Golgi network and more is present at the perinuclear recycling endosome. In polarized epithelial cells, in addition to the Golgi complex the recycling endosome represents an important sorting station in the biosynthetic secretory pathway for the delivery of proteins to the plasma membrane (Ang et al., 2004) . We recently showed that myosin VI is present at the recycling endosome in a polarized cell line derived from canine kidney (MDCK cells) , and as LNCaP cells are derived from prostate epithelial cells, they may have maintained this specialized delivery route through the recycling endosome to the plasma membrane.
Our observation that, out of the different myosin VIbinding partners that are expressed in LNCaP cells, only GIPC and LMTK2 co-immunoprecipitate with myosin VI is extremely important in the light of the recent observation that LMTK2 is a new candidate susceptibility gene for prostate cancer (Eeles et al., 2008) . We previously showed that myosin VI and LMTK2 function in the Rab11-positive recycling endosome in HeLa cells , and it is likely that both proteins have similar functions in LNCaP cells. LMTK2 appears to act as a transmembrane protein to recruit myosin VI to the surface of endosomes. The evidence that in LNCaP cells, myosin VI interacts with LMTK2, and both proteins have a role at the recycling endosome and are linked to prostate cancer progression, highlights the importance of the secretory pathway through the recycling endosome for prostate cancer pathology.
The targeting of myosin VI to CCS at the plasma membrane requires myosin VI binding to Dab2 (Spudich et al., 2007) (Morris et al., 2002) . However, in many prostate, breast and ovarian cancer cell lines that upregulate myosin VI expression, the expression of the tumour suppressor protein, Dab2, has been lost. At present, we do not know whether in these cell lines loss of Dab2 and upregulation of myosin are linked. The absence of Dab2 from LNCaP cells ensures that the myosin VI isoforms, LI-abc and LI-bc, which are normally recruited by Dab2 to CCS, are available for other intracellular function, such as protein secretion. Indeed, our results show (see Figures 6 and 7) that overexpression of not only the dominant-negative NI tail but also the LI-abc, LI-bc and LI-ab tail isoforms are able to inhibit secretion of PSA and VEGF from LNCaP cells, suggesting that all the different myosin VI isoforms have equal roles in protein secretion. Interestingly, in LNCaP cells, the absence of myosin VI in CCS does not affect clathrin-dependent endocytosis of the TfR or the EGFR, indicating that in these prostate cancer cells, which have lost apical-basolateral polarity, myosin VI is no longer required for clathrin-mediated endocytosis from the apical domain (Ameen and Apodaca, 2007) . The transition from apical-basolateral to planar polarity is required for the increase in cell motility that underlies the invasive dissemination of cancer cells. In prostate and ovarian cancer cells, knockdown of myosin VI has been shown to reduce cell migration and dissemination (Yoshida et al., 2004) . Thus, although the molecular mechanism of myosin VI function in cancer cell migration remains to be established, increased protein secretion is very likely to have a role in enhancing cell motility.
Materials and methods
Antibodies, cell lines and plasmids
The following antibodies were used: GFP (Molecular Probes, Eugene, Oregon, USA), AP2 (AP6, ABR, Golden, CO, USA), Rab5 (BD Transduction Laboratories, San Jose, CA, USA), TfR (Zymed, San Francisco, CA, USA), TGN46 (Serotec, Planegg, Germany), Dab2, androgen receptor, calregulin, calnexin, EGFR (all from Santa Cruz, Santa Cruz, CA, USA), anti-GIPC (Proteus Biosciences, Ramona, CA, USA), clathrin (Abcam, Cambridge, UK), PSA (Sigma, St Louis, MO, USA), myosin VI tail (Buss et al., 1998) , T6BP and NDP52 (Morriswood et al., 2007) , optineurin (Sahlender et al., 2005) and LMTK2 . LNCaP, HeLa and PNT1A cells from the European Collection of Cell Cultures (Salisbury, UK). Dab2-GFP (Morris et al., 2002) and GFPmyosin VI tails with (LI, exons abc) and without (NI) the large insert were described previously (Spudich et al., 2007) . Myosin VI tail LI constructs containing ab and bc exons were amplified by PCR from LNCaP cDNA and cloned into pEGFPC3 (Clontech, Montain View, CA, USA). Expression of myosin VI isoforms in HeLa cells, normal prostate (PNT1A) and prostate cancer (LNCaP) cells was assessed by reverse transcription PCR (Buss et al., 2001; Au et al., 2007) .
Cell culture and transfection
LNCaP cells grown in RPMI 1640 medium containing 10% fetal calf serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 10 mM Hepes and 1 mM sodium pyruvate were transfected using Lipofectamine 2000 (Invitrogen, Paisley, UK). Cells expressing GFP-tagged proteins were isolated by FACS sorting.
Knockdown of myosin VI by siRNA For efficient siRNA knockdown of myosin VI in LNCaP cells, Lipofectamine 2000 (Invitrogen) and ON-TARGET plus Smart pool siRNAs (Dharmacon, Lafayette, CO, USA) were used. The cells were transfected twice with siRNA on days 1 and 3, and on day 5 the efficiency of protein depletion was assessed by immunoblotting.
Immunofluorescence microscopy LNCaP and HeLa cells were grown on coverslips, transfected and after 24 h processed for immunofluorescence (Buss et al., 2001) . To remove cytosolic proteins, LNCaP and HeLa cells were first permeabilized with 0.05% saponin in cytosol buffer (Morris and Cooper, 2001 ), before fixation with 4% formaldehyde. Cells were visualized and photographed using a Zeiss LSM 510 confocal microscope (Carl Zeiss MicroImaging Inc., Tornwood, NY, USA).
Immuno-electron microscopy and morphometric analysis LNCaP and PNT1A cells maintained in growing conditions were fixed in a mixture of 2% paraformaldehyde and 0.2% glutaraldehyde or 2% paraformaldehyde and 1% acrolein in phosphate-buffered saline buffer and processed for ultra-thin cryosectioning (Puri et al., 2005) .
Immunoblotting and immunoprecipitation
LNCaP cells were lysed in 50 mM Tris (pH 7.5), 100 mM NaCl, 20 mM NaF, 20 mM Na 4 P 2 O 7 , 5 mM MgCl 2 , 5 mM ATP, 1 mM activated Na-o-vanadate, 1% Igepal CA-630 and protease inhibitor cocktail (Roche, Basel, Switzerland). Myosin VI was immunoprecipitated from the cleared lysate (15 min at 13 000 Â g) using polyclonal tail antibodies (Buss et al., 1998) , and the immunoprecipitated complexes analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis and immunoblotting. For co-immunoprecipitation of myosin VI and GFP-Dab2, LNCaP cells were transfected with GFP-Dab2 construct and 24 h later, FACSsorted into GFP-positive and GFP-negative populations. GFP-Dab2 was immunoprecipitated using GFP antibody; immunoprecipitation from GFP-negative cells was performed as control.
FACS-based endocytosis assays
Endocytic uptake and recycling assays in HeLa and LNCaP cells were performed as described (Peden et al., 2004) . For transferrin uptake, the cells were trypsinized and incubated in the medium with 50 mg/ml Tf-Alexa-647 for 30 min at 4 1C. After shifting the temperature to 37 1C for set time points, transferrin internalization was stopped by placing the samples on ice for 10 min. For recycling assay, cells were incubated with Tf-Alexa-647 for 30 min at 37 1C, washed and incubated at 37 1C with 100mg/ml unlabelled transferrin for various time points before fixing in 4% paraformaldehyde.
For epidermal growth factor (EGF) internalization, the cells were serum starved for 18 h, detached with non-enzymatic cell dissociation solution and incubated in serum-free medium containing 0.5 mg/ml EGF-Alexa-647 for 1 h, then washed in serum-free medium to remove unbound EGF. After shifting the temperature to 37 1C for set time points, internalization was stopped by placing cells on ice. Cell-surface-bound EGF was stripped using 0.5 M acetic acid/0.5 M NaCl and the cells were fixed with 4% paraformaldehyde. Cell-associated TfAlexa-647 and EGF-Alexa-647 were determined using FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).
EGFR degradation
LNCaP cells and HeLa cells were serum starved overnight, incubated in medium with 100 mg/ml cycloheximide for 2 h before stimulation with 100 ng/ml EGF for 0, 1 or 2 h. The cell lysates were blotted with antibodies to EGFR.
PSA/VEGF secretion assay LNCaP cells were transfected with myosin VI siRNA or dominant-negative myosin VI tails, and after 72 h the amounts of PSA and VEGF in medium were measured by ELISA (enzyme-linked immunosorbent assay), according to manufacturer's instructions (MP Biomedicals, Orangeburg, NY, USA and R&D Systems, Minneapolis, MN, USA). The cell number was quantified using Cell Titer-Blue dye (Promega, Madison, WI, USA) and EnVision HTS microplate reader (PerkinElmer, Waltham, MA, USA) using a 405 nm filter.
